Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Walnut Creek, CA
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Trumbull, CT
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Trumbull, CT
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Jacksonville, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Melbourne, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Miami, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Ocala, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Ocala, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Pembroke Pines, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
St. Petersburg, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Titusville, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Titusville, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
West Palm Beach, FL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Springfield, IL
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Worcester, MA
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Duluth, MN
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
St. Louis, MO
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
North Plainfield, NJ
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
North Plainfield, NJ
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Charlotte, NC
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Durham, NC
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Oklahoma City, OK
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Chattanooga, TN
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Corpus Christi, TX
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Edmonds, WA
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Edmonds, WA
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Renton, WA
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Tacoma, WA
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  1/25/2017
Novo Nordisk Investigational Site
mi
from
Charleston, WV
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 1/25/2017
Novo Nordisk Investigational Site
mi
from
Charleston, WV
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Birmingham, AL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Vestavia, AL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Vestavia, AL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Searcy, AR
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Searcy, AR
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Chula Vista, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Concord, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Concord, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Inglewood, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Inglewood, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Orange, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Santa Ana, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Santa Barbara, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Santa Monica, CA
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Aurora, CO
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Longmont, CO
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Longmont, CO
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Newark, DE
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Newark, DE
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Aventura, FL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Aventura, FL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Delray Beach, FL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Lake Mary, FL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Lake Mary, FL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Longwood, FL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Longwood, FL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Ocala, FL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Ocala, FL
Click here to add this to my saved trials
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  1/30/2017
Novo Nordisk Investigational Site
mi
from
Orlando, FL
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 1/30/2017
Novo Nordisk Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials